Test Catalog

Test Id : MMLRG

Order This Test

Antimicrobial Susceptibility, Acid-Fast Bacilli, Rapidly Growing, Varies

Download
Overview

Test Catalog

Useful For
Suggests clinical disorders or settings where the test may be helpful

Determination of susceptibility of rapidly growing mycobacteria to the antimicrobial agents on the test panel

Additional Tests
Lists tests that are always performed, at an additional charge, with the initial tests.

Test Id Reporting Name Available Separately Always Performed
SRG Susceptibility Rapid Grower No, (Bill Only) Yes

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

When this test is ordered, rapid grower susceptibility will be performed at an additional charge.

Special Instructions
Library of PDFs including pertinent information and forms related to the test

Method Name
A short description of the method used to perform the test

Minimum Inhibitory Concentration (MIC) by Microtiter Broth Dilution Method

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

Susc, AFB, Rapidly Growing

Aliases
Lists additional common names for a test, as an aid in searching

Acid-Fast Bacilli (AFB)

AFB (Acid-Fast Bacilli)

Antibiotic Susceptibility

Bacillus, Acid-Fast

MIC (Minimum Inhibitory Concentration)

Minimum Inhibitory Concentration (MIC)

Mycobacteria Antimicrobial Susceptibility (MIC) (Minimum Inhibitory Concentration)

Mycobacterium abscessus Susceptibility Testing

Mycobacterium chelonae Susceptibility Testing

Mycobacterium fortuitum Susceptibility Testing

Mycobacterium mucogenicum Susceptibility Testing

Rapid Growing Mycobacteria to Antimicrobial Agents

Susceptibility Testing

Clofazimine

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

When this test is ordered, rapid grower susceptibility will be performed at an additional charge.

Specimen Type
Describes the specimen type validated for testing

Varies

Additional Testing Requirements

CTB / Mycobacteria and Nocardia Culture, Varies or CTBID / Culture Referred for Identification, Mycobacterium and Nocardia, Varies must also be ordered and will be charged separately unless identification of organism is provided by the client.

Shipping Instructions

1. See Infectious Specimen Shipping Guidelines in Special Instructions.

2. Place specimen in a large infectious container (T146) and label as an etiologic agent/infectious substance.

Necessary Information

Specimen source and organism identification are required unless either CTB / Mycobacteria and Nocardia Culture, Varies or CTBID / Culture Referred for Identification, Mycobacterium and Nocardia, Varies is also ordered.

 

Identification to the species level is required for Mycobacterium species in order for the correct antimicrobial susceptibility drug panel to be selected. Identification to the genus level is sufficient for Nocardia species and other aerobic actinomycetes (eg, Gordonia species, Rhodococcus species).

ORDER QUESTIONS AND ANSWERS

Question ID Description Answers
Q00M0038 Specimen source (Required) and Organism Identification (Required unless concurrent identification test is ordered)

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Specimen Type: Organism

Supplies: Infectious Container, Large (T146)

Container/Tube: Middlebrook 7H10 agar slant or other appropriate media

Specimen Volume: Pure isolate

Collection Instructions: Organism must be in pure culture, actively growing.

Special Instructions
Library of PDFs including pertinent information and forms related to the test

Forms

If not ordering electronically, complete, print, and send a Microbiology Test Request (T244) with the specimen.

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory

See Specimen Required

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

Agar plate Reject

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Varies Ambient (preferred)
Refrigerated

Useful For
Suggests clinical disorders or settings where the test may be helpful

Determination of susceptibility of rapidly growing mycobacteria to the antimicrobial agents on the test panel

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

When this test is ordered, rapid grower susceptibility will be performed at an additional charge.

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

There are more than 100 species of rapidly growing mycobacteria and many are significant human pathogens (eg, Mycobacterium abscessus, Mycobacterium chelonae, Mycobacterium fortuitum). Rapidly growing mycobacteria cause a variety of infections including pulmonary infections, skin and soft tissue infections, and disseminated disease. Antimicrobial susceptibility testing of clinically significant rapidly growing mycobacteria is important to help guide patient care.

 

Antimicrobials tested in this assay are amikacin, cefoxitin, ciprofloxacin, clarithromycin, clofazimine, doxycycline, imipenem, linezolid, moxifloxacin, tigecycline, tobramycin, and trimethoprim/sulfamethoxazole.

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

 
Antimicrobial

Susceptible (mcg/mL)

Intermediate (mcg/mL)

Resistant (mcg/mL)

Amikacin

< or =16

32

> or =64

Cefoxitin

< or =16

32-64

> or =128

Ciprofloxacin

< or =1

2

> or =4

Clarithromycin

< or =2

4

> or =8

Clofazimine

No interpretations available

Doxycycline

< or =1

2-4

> or =8

Imipenem

< or =4

8-16

> or =32

Linezolid

< or =8

16

> or =32

Moxifloxacin

< or =1

2

> or =4

Tigecycline

No interpretations available

Tobramycin

< or =2

4

> or =8

Trimethoprim/Sulfamethoxazole

< or =2/38

-

> or =4/76

Interpretation
Provides information to assist in interpretation of the test results

Results are reported as the minimum inhibitory concentration in micrograms/mL. Interpretive criteria (susceptible, intermediate, or resistant) are reported according the Clinical and Laboratory Standards Institute (CLSI) guidelines.

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. Brown-Elliott BA and Pilley JV. Rapidly growing mycobacteria. Microbiol Spectr. 2017;5:1-19

2. Apiwattankul N, Flynn PM, Hayden RT, Adderson EE. Infections caused by rapidly growing mycobacteria spp in children and adolescents with cancer. J Pediatric Infect Dis Soc. 2015 Jun;4(2):104-113

3. Kasperbauer SH, De Groote MA. The treatment of rapidly growing mycobacterial infections. Clin Chest Med. 2015 Mar;36(1):67-78

Special Instructions
Library of PDFs including pertinent information and forms related to the test

Method Description
Describes how the test is performed and provides a method-specific reference

The method employed in this assay is broth microtiter dilution using a commercially available RAPMYCO2 plate. Antimicrobials included in the assay are tested according to CLSI guidelines.(CLSI. Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes. 3rd ed. CLSI standard M24. Clinical and Laboratory Standards Institute; 2018 and CLSI. Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes. CLSI supplement M62. Clinical and Laboratory Standards Institute; 2018)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Monday through Sunday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

12 to 28 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

1 year

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their account representative. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

87186

LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.

Test Id Test Order Name Order LOINC Value
MMLRG Susc, AFB, Rapidly Growing 29579-0
Result Id Test Result Name Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
MMLRG Susc, AFB, Rapidly Growing 29579-0

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | PHP Pdf | CMS Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports